Label Changes for:

Edarbi (azilsartan medoxomil) Tablets 

December 2011

Changes have been made to the WARNINGS, PRECAUTIONS and PATIENT PACKAGE INSERT sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011

 

 

WARNINGS AND PRECAUTIONS (revised)

*Fetal toxicity

  • Use of drugs that act on the rennin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death…

 

USE IN SPECIFIC POPULATIONS (revised)

Pregnancy
  • Pregnancy Category D

 

PATIENT COUNSELING INFORMATION (revised)

General Information
  • Pregnancy: Tell female patients of childbearing potential about the consequences of exposure to Edarbi during pregnancy…

 

PATIENT PACKAGE INSERT (revised)

What is the most important information I should know about Edarbi?
  • Edarbi can cause harm or death to your unborn baby.
  • Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant.
  • If you become pregnant while taking Edarbi, tell your doctor right away. Your doctor may switch you to a different medicine to treat your high blood pressure.
Hide
(web1)